Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

doi:10.1136/bmj.k3529

科研成果详情

题名	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
作者	Shen, Xian; Zhao, Bin
发表日期	2018-09-10
发表期刊	BMJ-BRITISH MEDICAL JOURNAL 影响因子和分区
语种	英语
原始文献类型	Article
其他关键词	OPEN-LABEL ; PREDICTIVE BIOMARKERS ; CELL CARCINOMA ; NIVOLUMAB ; DOCETAXEL ; MULTICENTER ; PEMBROLIZUMAB ; ATEZOLIZUMAB ; BLOCKADE ; MELANOMA
摘要	OBJECTIVE To evaluate the relative efficacy of programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors versus conventional drugs in patients with cancer that were PD-L1 positive and PD-L1 negative. DESIGN Meta-analysis of randomised controlled trials. DATA SOURCES PubMed, Embase, Cochrane database, and conference abstracts presented at the American Society of Clinical Oncology and European Society of Medical Oncology up to March 2018. REVIEW METHODS Studies of PD-1 or PD-L1 inhibitors (avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab) that had available hazard ratios for death based on PD-L1 positivity or negativity were included. The threshold for PD-L1 positivity or negativity was that PD-L1 stained cell accounted for 1% of tumour cells, or tumour and immune cells, assayed by immunohistochemistry staining methods. RESULTS 4174 patients with advanced or metastatic cancers from eight randomised controlled trials were included in this study. Compared with conventional agents, PD-1 or PD-L1 inhibitors were associated with significantly prolonged overall survival in both patients that were PD-L1 positive (n=2254, hazard ratio 0.66, 95% confidence interval 0.59 to 0.74) and PD-L1 negative (1920, 0.80, 0.71 to 0.90). However, the efficacies of PD-1 or PD-L1 blockade treatment in patients that were PD-L1 positive and PD-L1 negative were significantly different (P=0.02 for interaction). Additionally, in both patients that were PD-L1 positive and PD-L1 negative, the long term clinical benefits from PD-1 or PD-L1 blockade were observed consistently across interventional agent, cancer histotype, method of randomisation stratification, type of immunohistochemical scoring system, drug target, type of control group, and median follow-up time. CONCLUSIONS PD-1 or PD-L1 blockade therapy is a preferable treatment option over conventional therapy for both patients that are PD-L1 positive and PD-L1 negative. This finding suggests that PD-L1 expression status alone is insufficient in determining which patients should be offered PD-1 or PD-L1 blockade therapy.
出版者	BMJ PUBLISHING GROUP
出版地	LONDON
ISSN	1756-1833
EISSN	1756-1833
卷号	362 页码:k3529.
DOI	10.1136/bmj.k3529
页数	9
WOS类目	Medicine, General & Internal
WOS研究方向	General & Internal Medicine
WOS记录号	WOS:000445015400002
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	30201790
PMC记录号	PMC6129950
SCOPUSEID	2-s2.0-85053280573
ESI高被引论文	2020-09 ; 2020-11 ; 2021-01 ; 2021-03 ; 2021-05 ; 2021-07 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05 ; 2024-07 ; 2024-09 ; 2024-11
自科自定义期刊分类	T2(A)类
通讯作者地址	[Zhao, Bin]Center for Precision Medicine,Second Affiliated Hospital,Yuying Children's Hospital of Wenzhou Medical University,109 Xueyuan West Road,Wenzhou,325027,China
Scopus学科分类	Medicine (all)
引用统计	被引频次：228[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/14865
专题	第二临床医学院，附属第二医院、育英儿童医院
通讯作者	Zhao, Bin
作者单位	Center for Precision Medicine,Second Affiliated Hospital,Yuying Children's Hospital of Wenzhou Medical University,Wenzhou,325027,China
第一作者单位	第二临床医学院，附属第二医院、育英儿童医院
通讯作者单位	第二临床医学院，附属第二医院、育英儿童医院
第一作者的第一单位	第二临床医学院，附属第二医院、育英儿童医院
推荐引用方式 GB/T 7714	Shen, Xian,Zhao, Bin. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis[J]. BMJ-BRITISH MEDICAL JOURNAL,2018,362:k3529..
APA	Shen, Xian, & Zhao, Bin. (2018). Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ-BRITISH MEDICAL JOURNAL, 362, k3529..
MLA	Shen, Xian,et al."Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis".BMJ-BRITISH MEDICAL JOURNAL 362(2018):k3529..